{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:44:06Z","timestamp":1782603846781,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ajem.2017.07.022","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T15:16:48Z","timestamp":1499354208000},"page":"1389-1390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy"],"prefix":"10.1016","volume":"35","author":[{"given":"May Thuy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Stoianovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajem.2017.07.022_bb0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity: a focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.ajem.2017.07.022_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.01.014","article-title":"5-Fluorouracil-induced leukoencephalopathy with acute stroke-like presentation fulfilling criteria for recombinant tissue plasminogen activator therapy","volume":"23","author":"Kinno","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.ajem.2017.07.022_bb0015","first-page":"215","article-title":"Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion","volume":"11","author":"Li","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ajem.2017.07.022_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4174\/astr.2016.90.3.179","article-title":"Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy","volume":"9093","author":"Yi","year":"2016","journal-title":"Ann Surg Treat Res"},{"issue":"5","key":"10.1016\/j.ajem.2017.07.022_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3747\/co.v15i5.252","article-title":"The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy","volume":"15","author":"Cheung","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ajem.2017.07.022_bb0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000380849","article-title":"Severe generalized weakness, paralysis, and aphasia following administration of irinotecan and oxaliplatin during FOLFIRINOX chemotherapy","volume":"8","author":"Chandar","year":"2015","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ajem.2017.07.022_bb0035","article-title":"Posterior reversible encephalopathy syndrome associated with FOLFOX chemotherapy","author":"Marrone","year":"2013","journal-title":"Case Rep Oncol Med"},{"issue":"5","key":"10.1016\/j.ajem.2017.07.022_bb0040","first-page":"386","article-title":"A case of oxaliplatin-related posterior reversible encephalopathy syndrome","volume":"6","author":"Skelton","year":"2007","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.ajem.2017.07.022_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000008197","article-title":"Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study","volume":"44","author":"Serrano-Castro","year":"2000","journal-title":"Eur Neurol"},{"issue":"3","key":"10.1016\/j.ajem.2017.07.022_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1212\/WNL.51.3.899","article-title":"Brain infarction following 5-fluorouracil and cisplatin therapy","volume":"51","author":"Amrani","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ajem.2017.07.022_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke","volume":"77","author":"Navi","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ajem.2017.07.022_bb0060","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.STR.0000204041.13466.4c","article-title":"Distinguishing between stroke and mimic at the bedside: the brain attack study","volume":"37","author":"Hand","year":"2006","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.ajem.2017.07.022_bb0065","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.04.018","article-title":"Predictors of acute stroke mimics in 8,187 patients referred to a stroke service","volume":"22","author":"Merino","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"17","key":"10.1016\/j.ajem.2017.07.022_bb0070","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1212\/WNL.0b013e3181dad5a6","article-title":"Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia","volume":"74","author":"Chemyshev","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ajem.2017.07.022_bb0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/STROKEAHA.111.000126","article-title":"Safety of thrombolysis in stroke mimics: results from a multicenter cohort study","volume":"44","author":"Zinkstok","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2017.07.022_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/STR.0000000000000086","article-title":"Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"47","author":"Demaerschalk","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2017.07.022_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000838","article-title":"The TeleStroke Mimic (TM)-Score: a prediction rule for identifying stroke mimics evaluated in a telestroke network","volume":"3","author":"Ali","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajem.2017.07.022_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham Study","volume":"10","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2017.07.022_bb0095","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1186\/s40064-016-2976-9","article-title":"Adjuvant FOLFOX treatment for stage II colon cancer: how many cycles are enough?","volume":"5","author":"Tsai","year":"2016","journal-title":"SpringePlus"},{"key":"10.1016\/j.ajem.2017.07.022_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1345\/aph.18425","article-title":"Fluorouracil-induced neurotoxicity","volume":"34","author":"Pirzada","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.ajem.2017.07.022_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4143\/crt.2010.42.2.118","article-title":"A case of 5-fluorouracil induced encephalopathy","volume":"42","author":"Kwon","year":"2010","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ajem.2017.07.022_bb0110","first-page":"335","article-title":"5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine","volume":"31","author":"Advani","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajem.2017.07.022_bb0115","first-page":"1073","article-title":"Effect of the fluoropyrimidines 5-fluorouracil and doxifluridine on cellular uptake of thiamin","volume":"9","author":"Heier","year":"1989","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajem.2017.07.022_bb0120","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajem.2017.07.022_bb0125","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajem.2017.07.022_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3904\/kjim.2006.21.1.43","article-title":"Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency","volume":"21","author":"Baek","year":"2006","journal-title":"Korean J Intern Med"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073567571730551X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073567571730551X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:35:36Z","timestamp":1760024136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073567571730551X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S073567571730551X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2017.07.022","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2017.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}